Literature DB >> 11148050

Non-oxidative mechanisms are responsible for the induction of mutagenesis by reduction of Cr(VI) with cysteine: role of ternary DNA adducts in Cr(III)-dependent mutagenesis.

A Zhitkovich1, Y Song, G Quievryn, V Voitkun.   

Abstract

Intracellular reduction of carcinogenic Cr(VI) generates Cr-DNA adducts formed through the coordination of Cr(III) to DNA phosphates (phosphotriester-type adduct). Here, we examined the role of Cr(III)-DNA adducts in mutagenesis induced by metabolism of Cr(VI) with cysteine. Reduction of Cr(VI) caused a strong oxidation of 2', 7'-dichlorofluoroscin (DCFH) and extensive Cr-DNA binding but no DNA breakage. Cr-DNA adducts induced unwinding of supercoiled plasmids and structural distortions in the DNA helix as detected by decreased ethidium bromide binding. Propagation of Cr-treated pSP189 plasmids in human fibroblasts led to a dose-dependent formation of the supF mutants and inhibition of replication. Blocking of Cr(III)-DNA binding by occupation of DNA phosphates with Mg(2+) or by sequestration of Cr(III) by inorganic phosphate or EDTA eliminated mutagenic responses and restored a normal yield of replicated plasmids. Dissociation of Cr(III) from DNA by a phosphate-based reversal procedure returned mutation frequency to background levels. The mutagenic responses at the different phases of the reduction reaction were unrelated to the amount of reduced Cr(VI) but reflected the number and the spectrum of Cr(III)-DNA adducts that were formed. Ternary cysteine-Cr(III)-DNA adducts were approximately 4-5 times more mutagenic than binary Cr(III)-DNA adducts. Although intermediate reaction products (CrV/IV, thiyl radicals) were capable of oxidizing DCFH, they were insufficiently reactive to damage DNA. Single-base substitutions at G/C pairs were the predominant type of Cr-induced mutations. The majority of mutations occurred at the sites where G had adjacent purine in the 3' or 5' position. Overall, our results present the first evidence that Cr(III)-DNA adducts play the dominant role in the mutagenicity caused by the metabolism of Cr(VI) by a biological reducing agent.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11148050     DOI: 10.1021/bi0015459

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  24 in total

Review 1.  Chromium genotoxicity: A double-edged sword.

Authors:  Kristen P Nickens; Steven R Patierno; Susan Ceryak
Journal:  Chem Biol Interact       Date:  2010-04-27       Impact factor: 5.192

2.  Mismatch repair proteins are activators of toxic responses to chromium-DNA damage.

Authors:  Elizabeth Peterson-Roth; Mindy Reynolds; George Quievryn; Anatoly Zhitkovich
Journal:  Mol Cell Biol       Date:  2005-05       Impact factor: 4.272

3.  Reduction with glutathione is a weakly mutagenic pathway in chromium(VI) metabolism.

Authors:  David Guttmann; Graham Poage; Tatiana Johnston; Anatoly Zhitkovich
Journal:  Chem Res Toxicol       Date:  2008-11       Impact factor: 3.739

4.  FANCD2 monoubiquitination and activation by hexavalent chromium [Cr(VI)] exposure: activation is not required for repair of Cr(VI)-induced DSBs.

Authors:  Susan K Vilcheck; Susan Ceryak; Travis J O'Brien; Steven R Patierno
Journal:  Mutat Res       Date:  2006-08-08       Impact factor: 2.433

5.  Biologically relevant oxidants cause bound proteins to readily oxidatively cross-link at Guanine.

Authors:  Morwena J Solivio; Dessalegn B Nemera; Larry Sallans; Edward J Merino
Journal:  Chem Res Toxicol       Date:  2012-02-06       Impact factor: 3.739

6.  Resistance to apoptosis, increased growth potential, and altered gene expression in cells that survived genotoxic hexavalent chromium [Cr(VI)] exposure.

Authors:  Daryl E Pritchard; Susan Ceryak; Keri E Ramsey; Travis J O'Brien; Linan Ha; Jamie L Fornsaglio; Dietrich A Stephan; Steven R Patierno
Journal:  Mol Cell Biochem       Date:  2005-11       Impact factor: 3.396

7.  Rapid DNA double-strand breaks resulting from processing of Cr-DNA cross-links by both MutS dimers.

Authors:  Mindy F Reynolds; Elizabeth C Peterson-Roth; Ivan A Bespalov; Tatiana Johnston; Volkan M Gurel; Haley L Menard; Anatoly Zhitkovich
Journal:  Cancer Res       Date:  2009-01-13       Impact factor: 12.701

8.  Induction of pro-apoptotic and cell cycle-inhibiting genes in chromium (VI)-treated human lung fibroblasts: lack of effect of ERK.

Authors:  Susan Ceryak; Carla Zingariello; Travis O'Brien; Steven R Patierno
Journal:  Mol Cell Biochem       Date:  2004-01       Impact factor: 3.396

Review 9.  Genetic and epigenetic mechanisms in metal carcinogenesis and cocarcinogenesis: nickel, arsenic, and chromium.

Authors:  Konstantin Salnikow; Anatoly Zhitkovich
Journal:  Chem Res Toxicol       Date:  2007-10-30       Impact factor: 3.739

10.  Chromium reduces the in vitro activity and fidelity of DNA replication mediated by the human cell DNA synthesome.

Authors:  Heqiao Dai; Jianying Liu; Linda H Malkas; Jennifer Catalano; Srilakshmi Alagharu; Robert J Hickey
Journal:  Toxicol Appl Pharmacol       Date:  2009-01-23       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.